Evorpacept: a Phase 2 CD47 Blocker Uniquely Designed for Use in Combination Therapies to Safely Maximize Anti-Cancer Activity

Time: 11:30 am
day: Day One Track B AM


• ALX Oncology’s lead product candidate, evorpacept, is a next-generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain
• Evorpacept has demonstrated promising clinical responses and tolerability across a range of hematologic and solid malignancies in combination with targeted antibodies, pembrolizumab, and chemotherapy
• ALX is currently enrolling subjects in multiple randomized, phase 2 studies of evorpacept in solid tumors and hematological malignancies